Callan Family Office LLC increased its stake in Avantor, Inc. (NYSE:AVTR – Free Report) by 237.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 221,295 shares of the company’s stock after acquiring an additional 155,675 shares during the quarter. Callan Family Office LLC’s holdings in Avantor were worth $2,979,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the business. Signaturefd LLC grew its holdings in shares of Avantor by 19.8% during the first quarter. Signaturefd LLC now owns 5,470 shares of the company’s stock worth $89,000 after buying an additional 904 shares in the last quarter. Truist Financial Corp grew its holdings in shares of Avantor by 2.2% during the second quarter. Truist Financial Corp now owns 44,325 shares of the company’s stock worth $597,000 after buying an additional 959 shares in the last quarter. Xponance Inc. grew its holdings in shares of Avantor by 0.9% during the first quarter. Xponance Inc. now owns 114,422 shares of the company’s stock worth $1,855,000 after buying an additional 966 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Avantor by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 191,700 shares of the company’s stock worth $2,580,000 after buying an additional 1,000 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV grew its holdings in shares of Avantor by 1.4% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 83,661 shares of the company’s stock worth $1,356,000 after buying an additional 1,138 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.
Insider Buying and Selling
In other news, CAO Steven W. Eck sold 3,476 shares of the firm’s stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $11.39, for a total transaction of $39,591.64. Following the transaction, the chief accounting officer directly owned 55,068 shares in the company, valued at approximately $627,224.52. This trade represents a 5.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.20% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on Avantor
Avantor Trading Down 1.0%
NYSE AVTR opened at $13.41 on Friday. The firm’s 50-day moving average is $12.79 and its two-hundred day moving average is $13.41. Avantor, Inc. has a 12 month low of $10.82 and a 12 month high of $26.14. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.98 and a quick ratio of 0.67. The stock has a market capitalization of $9.14 billion, a P/E ratio of 13.54, a PEG ratio of 4.36 and a beta of 0.98.
Avantor (NYSE:AVTR – Get Free Report) last posted its earnings results on Friday, August 1st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Avantor had a net margin of 10.31% and a return on equity of 11.39%. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.25 EPS. On average, sell-side analysts anticipate that Avantor, Inc. will post 1.06 earnings per share for the current year.
Avantor Company Profile
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Featured Stories
- Five stocks we like better than Avantor
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Bassett Furniture: Buy Now, Sit Back, and Collect Dividends
- Stock Market Upgrades: What Are They?
- AST SpaceMobile’s Big Win: Shares Soar on New Deal With Verizon
- What Does Downgrade Mean in Investing?
- Catch the Next Bitcoin Rally With These 3 ETFs
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.